Desmond Padhi

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi request reprint The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals
    Desmond Padhi
    Department of Early Development Medical Sciences, Amgen Inc Thousand Oaks, CA 91320, USA
    Am J Ther 14:235-40. 2007
  2. doi request reprint Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
    Desmond Padhi
    Amgen Inc, Thousand Oaks, CA, USA
    J Bone Miner Res 26:19-26. 2011
  3. ncbi request reprint Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet
    Desmond Padhi
    Early Development, Department of Medical Sciences, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA
    Clin Drug Investig 34:537-44. 2014
  4. pmc A single-dose study of denosumab in patients with various degrees of renal impairment
    Geoffrey A Block
    Denver Nephrologists, PC, Clinical Research Division, Denver, CO, USA
    J Bone Miner Res 27:1471-9. 2012
  5. pmc An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects
    Desmond Padhi
    Early Development, Amgen Inc, One Amgen Center Dr, M S 38 3 A, Thousand Oaks, CA 91320, USA
    Pediatr Nephrol 27:1953-9. 2012
  6. ncbi request reprint Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride
    Desmond Padhi
    Department of Medical Sciences, Amgen Inc, Thousand Oaks, California 91320, USA
    Clin Pharmacokinet 48:303-11. 2009
  7. ncbi request reprint Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study
    Desmond Padhi
    Department of Early Development Medical Sciences, Amgen, Inc, Thousand Oaks, California, USA
    Clin Drug Investig 28:635-43. 2008
  8. ncbi request reprint Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers
    Desmond Padhi
    Department of Medical Sciences, Amgen Inc, Thousand Oaks, California 91320, USA
    Drugs R D 9:335-43. 2008
  9. ncbi request reprint An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis
    Desmond Padhi
    Amgen Inc, Thousand Oaks, California 91320, USA
    Clin Pharmacokinet 45:503-10. 2006
  10. ncbi request reprint No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara)
    Desmond Padhi
    Department of Early Development, Amgen Inc, Thousand Oaks, California, USA
    Clin Pharmacokinet 44:509-16. 2005

Detail Information

Publications20

  1. ncbi request reprint The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals
    Desmond Padhi
    Department of Early Development Medical Sciences, Amgen Inc Thousand Oaks, CA 91320, USA
    Am J Ther 14:235-40. 2007
    ..The observed effect supports the labeling statement that cinacalcet be taken with food, or shortly after a meal...
  2. doi request reprint Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
    Desmond Padhi
    Amgen Inc, Thousand Oaks, CA, USA
    J Bone Miner Res 26:19-26. 2011
    ....
  3. ncbi request reprint Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet
    Desmond Padhi
    Early Development, Department of Medical Sciences, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, 91320, USA
    Clin Drug Investig 34:537-44. 2014
    ....
  4. pmc A single-dose study of denosumab in patients with various degrees of renal impairment
    Geoffrey A Block
    Denver Nephrologists, PC, Clinical Research Division, Denver, CO, USA
    J Bone Miner Res 27:1471-9. 2012
    ..Supplementation of calcium and vitamin D is strongly recommended when patients initiate denosumab therapy, particularly in patients with reduced renal function...
  5. pmc An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects
    Desmond Padhi
    Early Development, Amgen Inc, One Amgen Center Dr, M S 38 3 A, Thousand Oaks, CA 91320, USA
    Pediatr Nephrol 27:1953-9. 2012
    ..There is limited knowledge of the effectiveness and safety profile of cinacalcet in pediatric patients with secondary hyperparathyroidism (sHPT) treated with dialysis...
  6. ncbi request reprint Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride
    Desmond Padhi
    Department of Medical Sciences, Amgen Inc, Thousand Oaks, California 91320, USA
    Clin Pharmacokinet 48:303-11. 2009
    ..PTH concentrations are greatest before dose administration when the cinacalcet concentration is lowest (24 hours after the previous day's dose). Nadir PTH levels occur approximately 2-3 hours after dosing...
  7. ncbi request reprint Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study
    Desmond Padhi
    Department of Early Development Medical Sciences, Amgen, Inc, Thousand Oaks, California, USA
    Clin Drug Investig 28:635-43. 2008
    ..This study aimed to evaluate the pharmacokinetics and pharmacodynamics of cinacalcet in subjects with different degrees of hepatic function...
  8. ncbi request reprint Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers
    Desmond Padhi
    Department of Medical Sciences, Amgen Inc, Thousand Oaks, California 91320, USA
    Drugs R D 9:335-43. 2008
    ..This study aimed to evaluate the potential inhibitory effects of cinacalcet on CYP3A activity using midazolam as a probe substrate in healthy volunteers...
  9. ncbi request reprint An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis
    Desmond Padhi
    Amgen Inc, Thousand Oaks, California 91320, USA
    Clin Pharmacokinet 45:503-10. 2006
    ....
  10. ncbi request reprint No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara)
    Desmond Padhi
    Department of Early Development, Amgen Inc, Thousand Oaks, California, USA
    Clin Pharmacokinet 44:509-16. 2005
    ..The objective of this study was to assess the effects of renal function and dialysis on the pharmacokinetics and pharmacodynamics of cinacalcet...
  11. ncbi request reprint Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole
    Robert Z Harris
    Department of Pharmacokinetics and Drug Metabolism, Amgen Inc, Thousand Oaks, California, USA
    Clin Pharmacokinet 46:495-501. 2007
    ..The objective of this study was to evaluate the pharmacokinetics of cinacalcet during treatment with a potent CYP3A4 inhibitor, ketoconazole...
  12. ncbi request reprint Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl
    Robert Z Harris
    Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Eur J Clin Pharmacol 63:159-63. 2007
    ..The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects...
  13. ncbi request reprint Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily
    Robert Z Harris
    Department of Pharmacokinetics and Drug Metabolism, Amgen Inc, Thousand Oaks, CA 91360, USA
    Am J Kidney Dis 44:1070-6. 2004
    ..This study investigated the pharmacokinetics, pharmacodynamics, safety, and tolerability of cinacalcet HCl over a dose range of 25 to 300 mg/d in patients receiving dialysis...
  14. ncbi request reprint Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin
    Desmond Padhi
    Department of Early Development Medical Sciences, Amgen Inc, Thousand Oaks, California 91320, USA
    Drugs R D 8:79-87. 2007
    ..The purpose of this study was to determine the pharmacokinetics/pharmacodynamics and tolerability of warfarin during cinacalcet coadministration...
  15. ncbi request reprint Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models
    Gondi N Kumar
    Pharmacokinetics and Drug Metabolism, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA, USA
    Drug Metab Dispos 32:1491-500. 2004
    ..Overall, the circulating and excreted metabolite profile of cinacalcet in humans was qualitatively similar to that observed in preclinical animal models...
  16. ncbi request reprint Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole
    Christopher Banfield
    Department of Clinical Pharmacology, Schering Plough Research Institute, Kenilworth, New Jersey 07033 0539, USA
    Clin Pharmacokinet 41:37-44. 2002
    ..This study was performed to assess the electrocardiographic safety and pharmacokinetics of desloratadine in combination with the CYP3A4 inhibitor ketoconazole...
  17. ncbi request reprint Lack of clinically relevant interaction between desloratadine and erythromycin
    Christopher Banfield
    Department of Clinical Pharmacology, Schering Plough Research Institute, Kenilworth, New Jersey 07033 0539, USA
    Clin Pharmacokinet 41:29-35. 2002
    ..To evaluate the bioavailability, cardiac safety and tolerability of desloratadine when given in combination with the CYP3A4 inhibitor erythromycin...
  18. ncbi request reprint Oral bioavailability of desloratadine is unaffected by food
    Samir Gupta
    Schering Plough Research Institute, Kenilworth, New Jersey 07033 0539, USA
    Clin Pharmacokinet 41:7-12. 2002
    ..To determine the effect of coadministration of food on the bioavailability of oral desloratadine...
  19. ncbi request reprint Desloratadine demonstrates dose proportionality in healthy adults after single doses
    Samir Gupta
    Schering Plough Research Institute, Kenilworth, New Jersey 07033 0539, USA
    Clin Pharmacokinet 41:1-6. 2002
    ..To evaluate the dose proportionality and linearity and pharmacokinetic profile of desloratadine after single oral doses over the range of 5 to 20mg...
  20. ncbi request reprint Pharmacology of darbepoetin alfa
    Iain C Macdougall
    Department of Renal Medicine, King s College Hospital, London, UK
    Nephrol Dial Transplant 22:iv2-iv9. 2007
    ..More rigorous studies will be needed to confirm these findings...